Journey Medical Up 21% on Rosacea-Drug Data
By Josh Beckerman
Shares of Journey Medical were up 21%, to $2.03, as it reported favorable topline Phase 1 study data for a papulopustular rosacea treatment it is developing in collaboration with Dr. Reddy's Laboratories.
Journey Medical said it is "very pleased" with the results for DFD-29, which indicate that it can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance.
The company expects topline data from Phase 3 trials in June, with a New Drug Application filing expected in the second half of 2023.
Journey Medical was founded by Fortress Biotech.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 13, 2023 14:00 ET (18:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Economic Data Back on the Agenda With CPI in View
-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations